Synaptogenix (NASDAQ:TAOX) Upgraded at Wall Street Zen

Synaptogenix (NASDAQ:TAOX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Synaptogenix Stock Performance

Shares of TAOX stock opened at $6.40 on Friday. Synaptogenix has a twelve month low of $1.84 and a twelve month high of $11.98. The firm’s 50-day moving average price is $7.26. The firm has a market cap of $45.63 million, a PE ratio of -0.32 and a beta of 1.93.

Synaptogenix (NASDAQ:TAOX) last released its quarterly earnings data on Friday, November 14th. The company reported ($1.56) earnings per share (EPS) for the quarter. The company had revenue of $2.41 million for the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.